Match!
Daniel J. Coleman
Oregon Health & Science University
12Publications
3H-index
32Citations
Publications 12
Newest
#1Daniel J. Coleman (OHSU: Oregon Health & Science University)H-Index: 3
#2Lina Gao (OHSU: Oregon Health & Science University)H-Index: 6
Last.Joshi J. Alumkal (OHSU: Oregon Health & Science University)H-Index: 25
view all 13 authors...
The BET bromodomain protein BRD4 is a chromatin reader that regulates transcription, including in cancer. In prostate cancer, specifically, the anti-tumor activity of BET bromodomain inhibition has been principally linked to suppression of androgen receptor (AR) function. MYC is a well-described BRD4 target gene in multiple cancer types, and prior work demonstrates that MYC plays an important role in promoting prostate cancer cell survival. Importantly, several BET bromodomain clinical trials ar...
4 CitationsSource
#2Daniel J. ColemanH-Index: 3
Last.Joshi J. AlumkalH-Index: 25
view all 5 authors...
Source
#1Daniel J. Coleman (OHSU: Oregon Health & Science University)H-Index: 3
#2Lina Gao (OHSU: Oregon Health & Science University)H-Index: 6
Last.Joshi J. Alumkal (OHSU: Oregon Health & Science University)H-Index: 25
view all 15 authors...
BET bromodomain inhibitors block prostate cancer cell growth at least in part through c-Myc and androgen receptor (AR) suppression. However, little is known about other transcriptional regulators whose suppression contributes to BET bromodomain inhibitor anti-tumor activity. Moreover, the anti-tumor activity of BET bromodomain inhibition in AR-independent castration-resistant prostate cancers (CRPC), whose frequency is increasing, is also unknown. Herein, we demonstrate that BET bromodomain inhi...
Source
#1Archana SehrawatH-Index: 6
#2Dae-Hwan KimH-Index: 2
Last.Joshi J. AlumkalH-Index: 25
view all 25 authors...
Source
#1Archana Sehrawat (OHSU: Oregon Health & Science University)H-Index: 6
#2Lina Gao (OHSU: Oregon Health & Science University)H-Index: 6
Last.Joshi J. Alumkal (OHSU: Oregon Health & Science University)H-Index: 25
view all 24 authors...
Medical castration that interferes with androgen receptor (AR) function is the principal treatment for advanced prostate cancer. However, clinical progression is universal, and tumors with AR-independent resistance mechanisms appear to be increasing in frequency. Consequently, there is an urgent need to develop new treatments targeting molecular pathways enriched in lethal prostate cancer. Lysine-specific demethylase 1 (LSD1) is a histone demethylase and an important regulator of gene expression...
20 CitationsSource
#1Carly J. King (OHSU: Oregon Health & Science University)H-Index: 4
#2Josha Woodward (OHSU: Oregon Health & Science University)H-Index: 3
Last.Joshi J. AlumkalH-Index: 25
view all 12 authors...
// Carly J. King 1 , Josha Woodward 2 , Jacob Schwartzman 2 , Daniel J. Coleman 2 , Robert Lisac 2 , Nicholas J. Wang 1 , Kathryn Van Hook 2 , Lina Gao 2 , Joshua Urrutia 2 , Mark A. Dane 1 , Laura M. Heiser 1, * and Joshi J. Alumkal 2, * 1 Department of Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Oregon Health and Science University, Portland, OR 97239, USA 2 Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA * These authors have cont...
1 CitationsSource
#1Archana SehrawatH-Index: 6
#2Lina GaoH-Index: 6
Last.Joshi J. AlumkalH-Index: 25
view all 19 authors...
Source
#1Lina Gao (OHSU: Oregon Health & Science University)H-Index: 6
#2Daniel J. Coleman (OHSU: Oregon Health & Science University)H-Index: 3
Last.Joshi J. Alumkal (OHSU: Oregon Health & Science University)H-Index: 25
view all 10 authors...
Background: While treatment options for patients with castration-resistant prostate cancer (CRPC) are expanding, one American man is still predicted to die every 19 minutes from this disease this year. Moreover, more widespread use of novel and more potent AR-targeting agents has led to increased clinical frequency of virulent androgen and AR-independent CRPC subsets(Small, Huang et al. 2015). Currently, there are limited treatment options for men with CRPC who are resistant to these AR-targetin...
Source
#1Daniel J. Coleman (OHSU: Oregon Health & Science University)H-Index: 3
#2Kathryn Van Hook (OHSU: Oregon Health & Science University)H-Index: 4
Last.Joshi J. Alumkal (OHSU: Oregon Health & Science University)H-Index: 25
view all 17 authors...
// Daniel J. Coleman 1 , Kathryn Van Hook 1 , Carly J. King 1, 2 , Jacob Schwartzman 1 , Robert Lisac 1 , Joshua Urrutia 1 , Archana Sehrawat 1 , Josha Woodward 1 , Nicholas J. Wang 1, 2 , Roman Gulati 3 , George V. Thomas 1 , Tomasz M. Beer 1 , Martin Gleave 4 , James E. Korkola 1, 2 , Lina Gao 1 , Laura M. Heiser 1, 2 , Joshi J. Alumkal 1 1 OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A 2 Department of Biomedical Engineering, Oregon Health & Science U...
6 CitationsSource
#1Daniel J. Coleman (OHSU: Oregon Health & Science University)H-Index: 3
#2Kathryn Van Hook (OHSU: Oregon Health & Science University)H-Index: 4
Last.Joshi J. Alumkal (OHSU: Oregon Health & Science University)H-Index: 25
view all 17 authors...
e16538Background: One emergent resistance mechanism to medical castration is intratumoral androgen synthesis that activates the androgen receptor (AR). This insight led to the development of the AR...
Source
12